# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
NeuroBo says DA-1241 data shows improved liver fibrosis and additive hepatoprotective effects when combined with semaglutide.
Data Will be Presented in Two Posters at the EASL Congress 2024
NeuroBo Pharmaceuticals (NASDAQ:NRBO) reported quarterly losses of $(1.32) per share which missed the analyst consensus estimat...
Maxim Group analyst Jason McCarthy initiates coverage on NeuroBo Pharmaceuticals (NASDAQ:NRBO) with a Buy rating and announc...
NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO), a clinical-stage biotechnology company focused on the transformation of cardiometa...
https://www.sec.gov/Archives/edgar/data/1638287/000155837024005018/tmb-20240412xs3.htm